Yunsi Olyslager

4.0k total citations
14 papers, 180 citations indexed

About

Yunsi Olyslager is a scholar working on Oncology, Hematology and Immunology. According to data from OpenAlex, Yunsi Olyslager has authored 14 papers receiving a total of 180 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 7 papers in Hematology and 5 papers in Immunology. Recurrent topics in Yunsi Olyslager's work include CAR-T cell therapy research (8 papers), Multiple Myeloma Research and Treatments (7 papers) and Biosimilars and Bioanalytical Methods (5 papers). Yunsi Olyslager is often cited by papers focused on CAR-T cell therapy research (8 papers), Multiple Myeloma Research and Treatments (7 papers) and Biosimilars and Bioanalytical Methods (5 papers). Yunsi Olyslager collaborates with scholars based in United States, Belgium and Germany. Yunsi Olyslager's co-authors include Sundar Jagannath, Saad Z. Usmani, Arnob Banerjee, Alicia J. Allred, Jesús G. Berdeja, Deepu Madduri, Enrique Zudaire, Jordan M. Schecter, Tzu‐Min Yeh and Marlene J. Carrasco-Alfonso and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Yunsi Olyslager

13 papers receiving 177 citations

Peers

Yunsi Olyslager
Comparison fields: 5 of 22
  • Oncology 153
  • Hematology 108
  • Molecular Biology 100
  • Immunology 28
  • Biomedical Engineering 23
Replace Tonia Nesheiwat with:
Tonia Nesheiwat United States
Myo Htut United States
Xugeng Wang China
Binod Dhakal United States
Omar Castañeda Puglianini United States
Martina Sersch China
Gabriel O. Cole United States
Daniella Cook United States
Ashley Turka United States
Myrna Nahas United States
Tonia Nesheiwat United States View profile →
Citations per field, relative to Yunsi Olyslager
Yunsi Olyslager · 1×
Citations per year, relative to Yunsi Olyslager
Yunsi Olyslager · 1×

Countries citing papers authored by Yunsi Olyslager

Since Specialization
Citations

This map shows the geographic impact of Yunsi Olyslager's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yunsi Olyslager with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yunsi Olyslager more than expected).

Fields of papers citing papers by Yunsi Olyslager

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yunsi Olyslager. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yunsi Olyslager. The network helps show where Yunsi Olyslager may publish in the future.

Co-authorship network of co-authors of Yunsi Olyslager

This figure shows the co-authorship network connecting the top 25 collaborators of Yunsi Olyslager. A scholar is included among the top collaborators of Yunsi Olyslager based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yunsi Olyslager. Yunsi Olyslager is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
# Work Indexed citations
1
Safety results from the phase 3 MajesTEC-7 study in patients (pts) with transplant ineligible/not intended newly diagnosed multiple myeloma (NDMM).
2024 ·Journal of Clinical Oncology ·Cyrille Touzeau, Meral Beksaç, Evangelos Terpos, Saad Z. Usmani, Amrita Krishnan, Inger S. Nijhof, Wojciech Janowski, Cyrille Hulin, Sebastian Grosicki, Michel Delforge, (unknown), Sarah Nagle, Yunsi Olyslager, Jonathan Miller, (unknown), Jamal Nasir Khan, Tobias Kampfenkel, Salomon Manier, Niels W.C.J. van de Donk
7
2
The patient experience of relapsed refractory multiple myeloma and perspectives on emerging therapies
2022 ·Cancer Reports ·Rebecca Crawford, Katharine S. Gries, Satish Valluri, John Fastenau, Ross Morrison, Tzu‐Min Yeh, Yunsi Olyslager, Jenna D. Goldberg, Jordan M. Schecter, Carolyn C. Jackson, William Deraedt, Lynda Doward
7
3
MonumenTAL-5: A Phase 3 Study of Talquetamab Versus Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Who Received ≥4 Prior Lines of Therapy, Including a Proteasome Inhibitor, an Immunomodulatory Drug, and an Anti-CD38 Monoclonal Antibody
2022 ·Blood ·Shaji Kumar, Alfred L. Garfall, Suzanne Trudel, Enrique M. Ocio, Emma Scott, Lin Huang, Xuewen Ma, Yunsi Olyslager, Payal Thakkar, Lixia Pei, Christoph Heuck, Evangelos Terpos
1
4
MajesTEC-7: A Phase 3, Randomized Study of Teclistamab + Daratumumab + Lenalidomide (Tec-DR) Versus Daratumumab + Lenalidomide + Dexamethasone (DRd) in Patients with Newly Diagnosed Multiple Myeloma Who Are Either Ineligible or Not Intended for Autologous Stem Cell Transplant
2022 ·Blood ·Amrita Krishnan, Salomon Manier, Evangelos Terpos, Saad Z. Usmani, Jamal Nasir Khan, Rachel Pearson, Suzette Girgis, Yue Guo, (unknown), Yunsi Olyslager, Tobias Kampfenkel, Niels W.C.J. van de Donk
19
5
Comparison of outcomes with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 versus real-world standard of care (RW SOC) for patients (pts) with triple-class exposed relapsed/refractory multiple myeloma (RRMM).
2021 ·Journal of Clinical Oncology ·Thomas Martin, Amrita Krishnan, Kwee Yong, Katja Weisel, Maneesha Mehra, Sandhya Nair, Keqin Qi, Anil Londhe, Joris Diels, Concetta Crivera, Carolyn C. Jackson, Yunsi Olyslager, Martin Vogel, Jordan M. Schecter, Arnob Banerjee, Satish Valluri, Saad Z. Usmani, Jesús G. Berdeja, Sundar Jagannath
5
6
Ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed/refractory multiple myeloma (R/R MM): Updated results from CARTITUDE-1.
2021 ·Journal of Clinical Oncology ·Saad Z. Usmani, Jesús G. Berdeja, Deepu Madduri, Andrzej Jakubowiak, Mounzer Agha, Adam D. Cohen, Parameswaran Hari, Tzu‐Min Yeh, Yunsi Olyslager, Arnob Banerjee, Carolyn C. Jackson, Alicia J. Allred, Enrique Zudaire, William Deraedt, Xiaoling Wu, Marlene J. Carrasco-Alfonso, Muhammad Akram, Yi Lin, Thomas G. Martin, Sundar Jagannath
26
7
Adjusted Comparison of Outcomes between Patients from CARTITUDE-1 versus Multiple Myeloma Patients with Prior Exposure to PI, Imid and Anti-CD-38 from a German Registry
2021 ·Cancers ·Maximilian Merz, Hartmut Goldschmidt, Parameswaran Hari, Mounzer Agha, Joris Diels, Francesca Ghilotti, (unknown), (unknown), (unknown), (unknown), Jordan M. Schecter, Carolyn C. Jackson, Yunsi Olyslager, Muhammad Akram, Tonia Nesheiwat, (unknown), Sundar Jagannath
10
8
UPDATED RESULTS FROM THE CARTITUDE-1 STUDY OF CILTACABTAGENE AUTOLEUCEL, A B-CELL MATURATION ANTIGEN–DIRECTED CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
2021 ·Hematology Transfusion and Cell Therapy ·(unknown), (unknown), Andrzej Jakubowiak, (unknown), AD Cohen, Deepu Madduri, Parameswaran Hari, T.‐J. Yeh, Yunsi Olyslager, Arnob Banerjee, (unknown), Alicia J. Allred, Enrique Zudaire, William Deraedt, Xiaoxiao Wu, Lida Pacaud, Muhammad Akram, Yukang Lin, Thomas G. Martin, Sundar Jagannath
12
9
Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE‐1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma
2021 ·SHILAP Revista de lepidopterología ·Thomas Martin, Amrita Krishnan, Kwee Yong, Katja Weisel, Maneesha Mehra, Sandhya Nair, Keqin Qi, Anil Londhe, Joris Diels, Concetta Crivera, Carolyn C. Jackson, Yunsi Olyslager, Martin Vogel, Jordan M. Schecter, Arnob Banerjee, Satish Valluri, Saad Z. Usmani, Jesús G. Berdeja, Sundar Jagannath
20
10
OAB-024: Updated results from CARTITUDE-1: Ciltacabtagene autoleucel, a B-cell maturation antigen–directed chimeric antigen receptor T (CAR-T) cell therapy, in relapsed/refractory multiple myeloma (RRMM)
2021 ·Clinical Lymphoma Myeloma & Leukemia ·Sundar Jagannath, Jesús G. Berdeja, Andrzej Jakubowiak, (unknown), Adam D. Cohen, Deepu Madduri, Parameswaran Hari, Tzu‐Min Yeh, Yunsi Olyslager, Arnob Banerjee, Carolyn C. Jackson, Alicia J. Allred, Enrique Zudaire, William Deraedt, Xiaoling Wu, Lida Pacaud, Muhammad Akram, Yi Lin, Thomas G. Martin, Saad Z. Usmani
1
11
Incidence, mitigation, and management of neurologic adverse events in patients with multiple myeloma (MM) treated with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-2.
2021 ·Journal of Clinical Oncology ·Hermann Einsele, Samir Parekh, Deepu Madduri, Bianca Santomasso, (unknown), Niels W.C.J. van de Donk, Bertrand Arnulf, María‐Victoria Mateos, Kevin C. De Braganca, Helen Varsos, Marlene J. Carrasco-Alfonso, Muhammad Akram, Nikoletta Lendvai, Carolyn C. Jackson, Yunsi Olyslager, Enrique Zudaire, (unknown), Dong Geng, Andrzej Jakubowiak, Adam D. Cohen
3
12
UPDATE OF CARTITUDE-1: A PHASE 1B/2 STUDY OF JNJ-68284528 (JNJ-4528), A B-CELL MATURATION ANTIGEN (BCMA)-DIRECTED CHIMERIC ANTIGEN RECEPTOR T (CAR-T) CELL THERAPY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM)
2020 ·Hematology Transfusion and Cell Therapy ·Jesús G. Berdeja, Deepu Madduri, (unknown), Indrajeet Singh, Enrique Zudaire, Tzu‐Min Yeh, Alicia J. Allred, Yunsi Olyslager, Arnob Banerjee, Judith D. Goldberg, Jordan M. Schecter, (unknown), (unknown), Marlene J. Carrasco-Alfonso, Syed Rizvi, (unknown), Andrzej Jakubowiak, Sundar Jagannath
5
13
Update of CARTITUDE-1: A phase Ib/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy, in relapsed/refractory multiple myeloma.
2020 ·Journal of Clinical Oncology ·Jesús G. Berdeja, Deepu Madduri, Saad Z. Usmani, Indrajeet Singh, Enrique Zudaire, Tzu‐Min Yeh, Alicia J. Allred, Yunsi Olyslager, Arnob Banerjee, Jeffrey L. Goldberg, Jordan M. Schecter, Dong Geng, Xiaoling Wu, Marlene J. Carrasco-Alfonso, Syed Rizvi, Frank Fan, Andrzej Jakubowiak, Sundar Jagannath
63
14
Final Analysis of a Phase 1b Study of Daratumumab in Combination with Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma (RRMM)
2019 ·Blood ·Ajai Chari, Sagar Lonial, Joaquín Martínez‐López, María‐Victoria Mateos, Joan Bladé, Lotfi Benboubker, Albert Oriol, Paula Rodríguez‐Otero, Luis Piñeiro, Andrzej Jakubowiak, Yunsi Olyslager, Jianping Wang, Ivo Nnane, Jon Ukropec, (unknown), Ming Qi, Philippe Moreau
1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tonia Nesheiwat Breakdown of academic impact, for papers by Myo Htut Breakdown of academic impact, for papers by Xugeng Wang Breakdown of academic impact, for papers by Binod Dhakal Breakdown of academic impact, for papers by Omar Castañeda Puglianini Breakdown of academic impact, for papers by Martina Sersch Breakdown of academic impact, for papers by Gabriel O. Cole Breakdown of academic impact, for papers by Daniella Cook Breakdown of academic impact, for papers by Ashley Turka Breakdown of academic impact, for papers by Myrna Nahas
Rankless by CCL
2026